Avitide

Avitide is the industry's premier biopharmaceutical affinity purification partner. The company develops a proprietary portfolio of AVIPure™ affinity ligands and end-to-end purification platforms for novel drug modalities including gene therapies, viral vaccines, bispecific antibodies, and cell-based therapies. Avitide works with partners from concept through commercial resin supply, delivering improved purity, yield, and manufacturing economics—reducing cost of goods and accelerating development timelines for biologic manufacturers. Acquired by Repligen in 2021.